The FDA granted accelerated approval to oral elafibranor (Iqirvo) for treating primary biliary cholangitis (PBC) in adults, drugmaker Ipsen announced on Monday. A first-in-class dual peroxisome ...

A compound comprising five agonists that together tackle weight loss, glucose reduction, insulin sensitization, and blood fat normalization has shown promise in mouse models of obesity. The compound ...

Findings showed a statistically significantly greater proportion of saroglitazar-treated patients achieved a biochemical response vs placebo (treatment difference, 48.5%; P .001). Topline data were ...

BRISBANE, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class i targeted and immune-mediated ...

Aleglitazar is a balanced dual peroxisome proliferator-activated receptor (PPAR) alpha/ gamma agonist, designed to optimize lipid and glycemic benefits. It is currently in Phase III development for ...

1 Laboratory Njoku, Department of Anesthesiology and Pain Medicine, Washington University in St. Louis, St. Louis, MO, United States 2 Department of Pathology and Immunology, Washington University in ...

Label comparisons began promptly with the accelerated U.S. FDA clearance of Gilead Sciences Inc.’s oral peroxisome proliferator-activated receptor (PPAR)-delta drug, Livdelzi (seladelpar), for primary ...

This indication was approved under accelerated approval based on a reduction of alkaline phosphatase. The Food and Drug Administration (FDA) has granted accelerated approval to Iqirvo ® (elafibranor) ...

The US Food and Drug Administration (FDA) has granted accelerated approval for Iqirvo (elafibranor; Ipsen) for treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid ...

PARIS, FRANCE, 10 June 2024 Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Iqirvo ® (elafibranor) 80 mg tablets ...